Image by Getty ImagesIn the year since its devastating hack, 23andMe has lost virtually all its stock value and most of its governing board — and somehow, things just keep getting worse for the one-time DNA kit wunderkind.As CEO Anne Wojcicki announced in a press release, 23andMe is not only laying off 40 percent of its remaining workforce — about 200 employees total — but also completely kiboshing its therapeutics program that was seeking to use AI and the company’s hoard of genetic information to develop new drugs.”We are taking…